
Traumatic Brain Injuries Treatment Market Trends
Traumatic Brain Injuries Treatment Market Research Report Information By Treatment (Immediate Emergency Care, Medications {Diuretics, Anti-Seizure Drugs, Coma-Inducing Drugs, Anti-Anxiety Agents, Anti-Depressant, Anti-Psychotics, Analgesic, Anti-Convulsants, Anti-Coagulants}, and Surgery {Removing Clotted Blood, Repairing Skull Fracture, Bleeding in the Brain, Opening a Window in the Skull, and...

Market Summary
As per Market Research Future Analysis, the traumatic brain injuries treatment market was valued at USD 1.99 Billion in 2024 and is projected to reach USD 4.37 Billion by 2035, growing at a CAGR of 7.42% from 2025 to 2035. Key drivers include technological advancements, increased clinical trials, and rising incidences of traumatic brain injuries due to sports, accidents, and violence. The market is significantly influenced by innovations such as Smart Quant Neuro 3D and Neuroshield CT, which enhance diagnostic capabilities and treatment efficiency.
Key Market Trends & Highlights
The market is witnessing significant growth driven by various factors.
- Traumatic brain injuries account for 2.8 million emergency visits annually in the US.
- Surgery segment dominated the market with 35% revenue share in 2023.
- Medications are the fastest-growing category due to their effectiveness in early treatment.
- North America holds the largest market share, driven by advanced healthcare facilities and government initiatives.
Market Size & Forecast
2024 Market Size | USD 1.99 Billion |
2035 Market Size | USD 4.37 Billion |
CAGR | 7.42% |
Largest Regional Market Share in 2024 | North America |
Major Players
Key players include Zimmer Biomet, Neuren Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Medicortex, and BrainScope Company, Inc.
Market Trends
The growing traumatic brain injuries is driving the market growth
Market CAGR for traumatic brain injury treatment is driven by rising sports injuries, falls, gunshot wounds, domestic violence, and road traffic accidents. As per the CDC, traumatic brain injuries are responsible for 2.8 million accidents and emergency department visits annually in the US. Furthermore, as per Stanford Children's Health, around 3.5 million sports-related wounds are registered yearly among children in the US, and about 21% of all are traumatic brain injuries.
Thus, increasing cases of traumatic brain injuries due to sports injuries, road accidents, and assaults are anticipated to fuel the market. The COVID-19 pandemic had a short-term and moderate impact on the market by directly affecting demand & production, disrupting the supply chain, and growth of the financial burden on firms.
Rising demand for minimally invasive neuro procedures owing to less pain and chances of infection and speedy recovery is expected to boost the demand for TBIs assessment and management devices. An increasing number of enterprises and programs being undertaken by the governments of different regions about brain injuries are expected to fuel the market growth.
For instance, as an initiative toward traumatic brain injuries treatment, the Brain Injury Association of America (BIAA) organizes a national public awareness campaign every March to emphasize the importance of acknowledging the impact of brain injuries.
Furthermore, the growing population and rising per capita incomes have changed consumer demand for highly sophisticated and technologically advanced products and equipment. The increase in health awareness campaigns and programs that motivate individuals to take adequate care of their fitness and be more conscious of the diseases that can be carried on by utilizing certain products is a significant factor that drives the traumatic brain injuries treatment market revenue.
In addition, the increasing incidence of TBIs due to road accidents and falls in developed and developing regions has driven the establishment of technologically advanced products in the market. For instance, BrainScope, a U.S.-based company, has been granted over USD 32 million from the US Department of Defense research contracts to develop its BrainScope One device. It is an EEG-based non-invasive technology that enables decision-making on the spot.
The increasing prevalence of traumatic brain injuries necessitates a multifaceted approach to treatment, emphasizing the importance of early intervention and rehabilitation strategies.
Centers for Disease Control and Prevention (CDC)
Traumatic Brain Injuries Treatment Market Market Drivers
Market Growth Projections
Rising Geriatric Population
The aging population is a critical driver of the Global Traumatic Brain Injuries Treatment Market Industry. As individuals age, they become more susceptible to falls and other accidents that can result in traumatic brain injuries. This demographic shift is expected to increase the demand for treatment options tailored to older adults. In response, healthcare systems are adapting to provide specialized care for this population, including rehabilitation services and cognitive therapies. The growing geriatric population is likely to contribute to the market's expansion, as the need for effective treatment solutions becomes increasingly apparent.
Growing Awareness and Education
The Global Traumatic Brain Injuries Treatment Market Industry benefits from increasing awareness and education regarding brain injuries. Public health campaigns and educational initiatives aim to inform individuals about the risks and prevention strategies associated with traumatic brain injuries. This heightened awareness leads to earlier diagnosis and treatment, ultimately improving patient outcomes. Healthcare providers are also emphasizing the importance of rehabilitation and follow-up care, which further supports market growth. As communities become more informed, the demand for effective treatment options is likely to rise, fostering a more robust market environment.
Government Initiatives and Funding
Government initiatives and funding significantly influence the Global Traumatic Brain Injuries Treatment Market Industry. Various governments are recognizing the need to address the growing burden of traumatic brain injuries and are allocating resources to research, prevention, and treatment programs. For example, funding for clinical trials and innovative treatment methods is increasing, which may lead to breakthroughs in care. Additionally, policies aimed at improving access to healthcare services for brain injury patients are being implemented. Such initiatives not only enhance treatment availability but also stimulate market growth by encouraging the development of new therapies and technologies.
Advancements in Treatment Technologies
Technological advancements play a pivotal role in shaping the Global Traumatic Brain Injuries Treatment Market Industry. Innovations in neuroimaging, surgical techniques, and rehabilitation technologies enhance the ability to diagnose and treat traumatic brain injuries effectively. For instance, the development of minimally invasive surgical procedures has improved patient outcomes and reduced recovery times. Furthermore, the integration of artificial intelligence in treatment protocols is expected to optimize therapeutic approaches. As these technologies evolve, they are likely to attract investment and research, contributing to the market's projected growth to 4.39 USD Billion by 2035, with a CAGR of 7.45% from 2025 to 2035.
Increasing Incidence of Traumatic Brain Injuries
The Global Traumatic Brain Injuries Treatment Market Industry is experiencing growth driven by the rising incidence of traumatic brain injuries. Factors such as increased participation in contact sports, road traffic accidents, and falls contribute to this trend. In 2024, the market is projected to reach 1.99 USD Billion, reflecting the urgent need for effective treatment options. As awareness of the long-term effects of brain injuries grows, healthcare providers are focusing on innovative therapies and rehabilitation techniques. This heightened focus on treatment options is likely to drive market expansion, as stakeholders seek to address the needs of an increasing patient population.
Market Segment Insights
Traumatic Brain Injuries Treatment Insights
The traumatic brain injuries treatment market segmentation, based on treatment, includes (immediate emergency care, medications diuretics, anti-seizure drugs, coma-inducing drugs, anti-anxiety agents, anti-depressant, anti-psychotics, analgesics, anti-convulsants, anti-coagulants, and surgery {removing clotted blood, opening a window in the skull, repairing skull fracture, bleeding in the brain, and rehabilitation.
The surgery segment dominated the market, accounting for 35% of market revenue (0.64 Billion). In developing economies, category growth is driven by the growing occurrence of brain injuries among people due to trauma or accidents. However, medications are the fastest-growing category over the forecast period as it provides early and effective treatment.
Traumatic Brain Injuries Treatment End-User Insights
The traumatic brain injuries treatment market segmentation, based on end-user, includes hospitals, neurologists, independent pharmacies, rehabilitative center treatment, and others. The hospitals category generated the most income. This is due to an expansion in the number of brain surgeries performed in hospitals and an increase in the prevalence of TBI patients across the globe. Hospitals are well-equipped with technologically advanced devices that professional neurologists use. However, a neurologist is the fastest-growing category as most brain surgeries can be performed by a neurologist, as these procedures turn out to be more advanced and less invasive.
Figure 1 Traumatic Brain Injuries Treatment Market, by End-User, 2023 & 2032 (USD Billion)
Source Secondary Research, MRFR Database, Primary Research, and Analyst Review
Get more detailed insights about Traumatic Brain Injuries Treatment Market Research Report - Forecast till 2032
Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American traumatic brain injuries treatment market will dominate over the forecast period, owing to the existence of well-established healthcare facilities in the region, growing government initiatives, awareness campaigns regarding brain injuries, and greater incidence of TBIs in this region. Further, the US traumatic brain injuries treatment market held the largest market share, and the Canada traumatic brain injuries treatment market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 TRAUMATIC BRAIN INJURIES TREATMENT MARKET SHARE BY REGION 2023 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe traumatic brain injuries treatment market accounts for the second-largest market share due to the growing patient affordability, have together resulted in a significant number of interventional procedures in the region. Further, the German traumatic brain injuries treatment market held the largest market share, and the UK traumatic brain injuries treatment market was the fastest growing market in the European region.
The Asia-Pacific traumatic brain injuries treatment market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to an expansion in the incidence of road accidents and violence. Moreover, China traumatic brain injuries treatment market held the largest market share, and the Indian traumatic brain injuries treatment market was the fastest-growing market in the Asia-Pacific region.
Key Players and Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the traumatic brain injuries treatment market grow even more. Market participants are also undertaking numerous strategic activities to expand their footprint, with important market developments including new product establishments, mergers and acquisitions, higher investments, contractual agreements, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the traumatic brain injury treatment industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the traumatic brain injury treatment industry to benefit clients and increase the market sector. In recent years, the traumatic brain injury treatment industry has offered some of the most significant advantages to medicine. Major players in the traumatic brain injuries treatment market, including Zimmer Biomet, Neuren Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Medicortex Finland Oy, AMARANTUS BIOSCIENCE HOLDINGS, INC., Stemedica Cell Technologies, Inc., and others, are attempting to increase market demand by investing in research and development operations.
Integra LifeSciences Holdings Corp is a medical technology firm that develops and manufactures engineered collagen-based product lines. The firm's portfolio comprises advanced wound care, surgical instruments, specialty metal implants, orthobiologic products, dermal regeneration products, tissue-engineered injury dressings, and nerve and tendon repair products. Its neurosurgery products such as ultrasonic surgery systems, systems for measuring several brain parameters, cranial stabilization and brain retraction systems, and others.
Integra's products find application in neurosurgery, orthopedic extremity surgery, and reconstructive and general surgery. Integra serves outpatient surgery centers, hospitals, physicians, veterinarians and dental practices. The firm markets its solutions through direct market representatives and an extensive network of distributors ly. In September 2019, Integra Life Sciences completed the acquisition of Rebound Therapeutics, a manufacturer of disposable medical devices. With this acquisition, the company developed new products and a minimally invasive platform for neurosurgery.
Nihon Kohden Corp (Nihon Kohden) develops, manufactures and commercializes electronic medical equipment and other systems to support treatment in clinical areas of emergency response, testing, diagnosis, treatment, and rehabilitation. Its major products include patient monitors, electroencephalographs, evoked potential and electromyograph systems, electrocardiographs, defibrillators and hematology analyzers.
These products find applications in health management, home medical care, nursing and basic medical research. The company operates through branch offices and direct sales personnel in Japan and subsidiaries and distributors across the globe. Nihon Kohden is headquartered in Tokyo, Japan. In June 2019, Nihon Kohden launched a wireless Electroencephalogram (EEG) headset in the US called VitalEEG to promptly assess brain activity in unconscious patients.
Key Companies in the Traumatic Brain Injuries Treatment Market market include










Industry Developments
- Q2 2024: BioDirection Receives FDA Breakthrough Device Designation for Tbit System for Traumatic Brain Injury BioDirection announced that its Tbit System, a rapid point-of-care blood test for traumatic brain injury, received Breakthrough Device Designation from the U.S. FDA, supporting expedited development and review.
- Q2 2024: Oculogica Receives FDA Clearance for EyeBOX 2.0, a Non-Invasive Concussion Diagnostic Device Oculogica announced FDA 510(k) clearance for EyeBOX 2.0, a non-invasive device designed to aid in the diagnosis of concussion and traumatic brain injury using eye-tracking technology.
- Q1 2024: Banyan Biomarkers Announces Partnership with Abbott to Advance Blood Test for Traumatic Brain Injury Banyan Biomarkers entered a partnership with Abbott to further develop and commercialize a blood test for the rapid detection of traumatic brain injury, aiming to improve emergency room diagnostics.
- Q2 2024: BioDirection Secures $20 Million Series C Financing to Advance Tbit System for Traumatic Brain Injury BioDirection raised $20 million in Series C funding to support clinical trials and commercialization of its Tbit System, a rapid blood test for traumatic brain injury.
- Q1 2024: BrainScope Announces CE Mark Approval for Next-Generation BrainScope One Device BrainScope received CE Mark approval for its next-generation BrainScope One device, enabling commercialization in the European Union for the assessment of traumatic brain injury.
- Q2 2024: Neurotrauma Sciences Appoints Dr. Michael Frank as Chief Medical Officer Neurotrauma Sciences announced the appointment of Dr. Michael Frank as Chief Medical Officer to lead clinical development of its pipeline for traumatic brain injury therapeutics.
- Q1 2024: BioDirection Announces Opening of New Manufacturing Facility for Tbit System BioDirection opened a new manufacturing facility dedicated to the production of its Tbit System, supporting anticipated commercial demand for traumatic brain injury diagnostics.
- Q2 2024: Oculogica Partners with Mayo Clinic to Advance Eye-Tracking Diagnostics for Traumatic Brain Injury Oculogica entered a partnership with Mayo Clinic to further validate and expand the clinical use of its EyeBOX technology for diagnosing traumatic brain injury.
- Q1 2024: Banyan Biomarkers Receives U.S. Army Contract to Develop TBI Blood Test for Battlefield Use Banyan Biomarkers was awarded a contract by the U.S. Army to develop a portable blood test for rapid detection of traumatic brain injury in military settings.
- Q2 2024: Neurotrauma Sciences Raises $30 Million Series B to Advance TBI Drug Candidates Neurotrauma Sciences closed a $30 million Series B funding round to support clinical trials of its lead drug candidates for the treatment of traumatic brain injury.
- Q1 2024: BrainScope Announces Partnership with U.S. Department of Defense for TBI Assessment Technology BrainScope entered a partnership with the U.S. Department of Defense to deploy its TBI assessment technology in military healthcare settings.
- Q2 2024: Oculogica Closes $15 Million Series A Funding to Expand EyeBOX Commercialization Oculogica raised $15 million in Series A funding to accelerate the commercialization and clinical adoption of its EyeBOX device for traumatic brain injury diagnosis.
Future Outlook
Traumatic Brain Injuries Treatment Market Future Outlook
The Global Traumatic Brain Injuries Treatment Market is projected to grow at a 7.42% CAGR from 2025 to 2035, driven by advancements in medical technology, increasing awareness, and rising incidence rates.
New opportunities lie in:
- Develop innovative rehabilitation technologies to enhance recovery outcomes.
- Invest in telemedicine solutions for remote patient monitoring and support.
- Explore partnerships with research institutions for cutting-edge treatment methodologies.
By 2035, the market is expected to exhibit robust growth, reflecting advancements in treatment and increased healthcare investments.
Market Segmentation
Traumatic Brain Injuries Treatment Outlook
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Traumatic Brain Injuries Treatment End-User Outlook
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Traumatic Brain Injuries Treatment Regional Outlook
- US
- Canada
Report Scope
Report Attribute/Metric | Details |
Market Size 2024 | USD 1.99 Billion |
Market Size 2035 | 4.37 (Value (USD Billion)) |
Compound Annual Growth Rate (CAGR) | 7.42% (2025 - 2035) |
Base Year | 2024 |
Market Forecast Period | 2025 - 2035 |
Historical Data | 2018- 2022 |
Market Forecast Units | Value (USD Billion) |
Report Coverage | Market Competitive Landscape, Growth Factors, Revenue Forecast, and Trends |
Segments Covered | Treatment, End-User and Region |
Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
Key Companies Profiled | Zimmer Biomet, Neuren Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Medicortex Finland Oy, AMARANTUS BIOSCIENCE HOLDINGS, INC., Stemedica Cell Technologies, Inc., BANYAN BIOMARKERS, INC., BioDirection, QuesGen Systems, Inc., and Neural Analytics, Inc. |
Key Market Opportunities | Numerous clinical trials are being conducted to develop traumatic brain injuries. |
Key Market Dynamics | Extensive research and development activities |
Market Size 2025 | 2.14 (Value (USD Billion)) |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
How much is the traumatic brain injuries treatment market?
The traumatic brain injuries treatment market size was valued at USD 1.84 Billion in 2023.
What is the growth rate of the traumatic brain injury treatment market?
The market is projected to grow at a CAGR of 7.42% during the forecast period, 2024-2032.
Which region held the largest market share in the traumatic brain injuries treatment market?
North America had the largest share of the market
Who are the key players in the traumatic brain injury treatment market?
The key players in the market are Medicortex Finland Oy, AMARANTUS BIOSCIENCE HOLDINGS, INC., Stemedica Cell Technologies, Inc., BANYAN BIOMARKERS, INC., BioDirection, QuesGen Systems, Inc., and Neural Analytics, Inc.
Which treatment led to the traumatic brain injuries treatment market?
The surgery category dominated the market in 2022.
Which end-user had the largest traumatic brain injuries treatment market share?
The hospitals had the most extensive market share.
-
Table of Contents
-
Chapter 1. Report Prologue
-
Chapter 2. Market Introduction
- Definition
-
Scope of the Study
- Research Objective
- Assumptions
- Limitations
-
Chapter 3. Research Methodology
- Introduction
- Primary Research
- Secondary Research
- Market Size Estimation
-
Chapter 4. Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Macroeconomic Indicators
- Technology Trends & Assessment
-
Chapter 5. Market Factor Analysis
-
Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Value Chain Analysis
- Investment Feasibility Analysis
- Pricing Analysis
-
Porter’s Five Forces Analysis
-
Chapter 6. Global Traumatic Brain Injury Treatment Market , by Treatment
- Introduction
- Immediate emergency care
-
Market Estimates & Forecast, by Region, 2023-2032
-
Market Estimates & Forecast, by Country, 2023-2032
- Medications
-
Market Estimates & Forecast, by Region, 2023-2032
-
Market Estimates & Forecast, by Country, 2023-2032
-
6.3.1 Diuretics
-
Market Estimates & Forecast, by Region, 2023-2032
-
Market Estimates & Forecast, by Country, 2023-2032
-
Anti-seizure drugs
- Coma-inducing drugs
-
Anti-seizure drugs
-
Market Estimates & Forecast, by Region, 2023-2032
- Anti-Anxiety Agent
-
Market Estimates & Forecast, by Region, 2023-2032
-
Market Estimates & Forecast, by Country, 2023-2032
-
Anti-Depressants
- Anti-Psychotics
-
Anti-Depressants
-
Market Estimates & Forecast, by Country, 2023-2032
-
Analgesic
- Anti-Convulsants,
- Anti-Coagulants
- Surgery
-
Analgesic
-
6.4.1 Removing clotted blood (hematomas)
-
Market Estimates & Forecast, by Region, 2023-2032
-
Market Estimates & Forecast, by Country, 2023-2032
-
Repairing skull fractures
- Bleeding in the brain
- Opening a window in the skull
- Rehabilitation
-
Repairing skull fractures
-
Chapter 7. Global Traumatic Brain Injury Treatment Market , by End-User
- Introduction
- Hospitals
-
Market Estimates & Forecast, by Country, 2023-2032
- Neurologist
-
Market Estimates & Forecast, by Country, 2023-2032
- Independent Pharmacies
-
7.5 Rehabilitative Center Treatment
-
Market Estimates & Forecast, by Country, 2023-2032
- Other
-
Chapter 8. Global Traumatic Brain Injury Treatment Market , by Region
- Introduction
-
Americas
- North America
- South America
-
Europe
- Western Europe
- Eastern Europe
-
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
-
Middle East & Africa
- Middle East
- Africa
-
Chapter 9 Company Landscape
-
- Introduction
- Market Share Analysis
- Key Development & Strategies
-
Chapter 10. Company Profiles
-
Zimmer Biomet
- Company Overview
- Product Overview
- Financials Overview
- Key Developments
- SWOT Analysis
-
Neuren Pharmaceuticals Ltd
- Company Overview
- Product Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Oxygen Biotherapeutics Inc
- Company Overview
- Product Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
TEVA Pharmaceutical Industries Ltd
- Company Overview
- Product Overview
- Financial Overview
- Key Development
- SWOT Analysis
-
Ischemic
- Company Overview
- Product Overview
- Financial overview
- Key Developments
- SWOT Analysis
-
Grace Laboratories LLC
- Company Overview
- Product Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Cognosci
- Overview
- Product Overview
- Financial Overview
- Key Developments
- SWOT Analysis
-
Medicortex
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Amarantus BioScience Holdings
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Aldagen
- Product Overview
- Financials
- Key Developments
- NeuroScience Pharmaceuticals
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Targacept
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
BioDirection, Inc
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
QuesGen Systems, Inc
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
BrainScope Company, Inc
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Neural Analytics, Inc
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Oculogica
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
BrainScope Company, Inc
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Silver Creek Pharmaceuticals Inc
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Stemedica Cell Technologies Inc
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Banayan Biomarkers Inc
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Vasopharm GmbH
- Overview
- Product Overview
- Financials
- Key Developments
- SWOT Analysis
-
Zimmer Biomet
-
Chapter 11 MRFR Conclusion
-
Key Findings
- From CEO’s View point
- Unmet Needs of the Market
- Key Companies to Watch
- Predictions for the Traumatic Brain Injury Treatment Market
-
Key Findings
-
Chapter 12. Appendix
-
-
List of Tables and Figures
- LIST OF TABLES
- Table 1 Global Traumatic Brain Injury Treatment Market Synopsis, 2023-2032
- Table 2 Global Traumatic Brain Injury Treatment Market Estimates and Forecast, 2023-2032 (USD Million)
- Table 3 Global Traumatic Brain Injury Treatment Market , by Region, 2023-2032 (USD Million)
- Table 4 Global Traumatic Brain Injury Treatment Market , by Treatment , 2023-2032 (USD Million)
- Table 5 Global Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million)
- Table 6 North America: Traumatic Brain Injury Treatment Market , by Treatment , 2023-2032 (USD Million)
- Table 7 North America: Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million)
- Table 8 US: Traumatic Brain Injury Treatment Market , by Treatment , 2023-2032 (USD Million)
- Table 9 US: Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million)
- Table 10 Canada: Traumatic Brain Injury Treatment Market ,by Treatment , 2023-2032 (USD Million)
- Table 11 Canada: Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million)
- Table 12 South America: Traumatic Brain Injury Treatment Market , by Treatment , 2023-2032 (USD Million)
- Table 13 South America: Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million)
- Table 14 Europe: Traumatic Brain Injury Treatment Market , by Treatment , 2023-2032 (USD Million)
- Table 15 Europe: Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million)
- Table 16 Western Europe: Traumatic Brain Injury Treatment Market , by Treatment , 2023-2032 (USD Million)
- Table 17 Western Europe: Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million)
- Table 20 Eastern Europe: Traumatic Brain Injury Treatment Market , by Treatment , 2023-2032 (USD Million)
- Table 19 Eastern Europe: Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million)
- Table 20 Asia-Pacific: Traumatic Brain Injury Treatment Market , by Treatment , 2023-2032 (USD Million)
- Table 21 Asia-Pacific: Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million)
- Table 22 Middle East & Africa: Traumatic Brain Injury Treatment Market , by Treatment, 2020-2027 (USD Million)
- Table 23 Middle East & Africa: Traumatic Brain Injury Treatment Market , by End-User, 2023-2032 (USD Million) LIST OF FIGURES
- Figure 1 Research Process
- Figure 2 Segmentation for Global Traumatic Brain Injury Treatment Market
- Figure 3 Segmentation Market Dynamics for Global Traumatic Brain Injury Treatment Market
- Figure 4 Global Traumatic Brain Injury Treatment Market Share, by Treatment , 2020
- Figure 5 Global Traumatic Brain Injury Treatment Market Share, by End-User, 2020
- Figure 6 Global Traumatic Brain Injury Treatment Market Share, by Region, 2020
- Figure 7 North America: Traumatic Brain Injury Treatment Market Share, by Country, 2020
- Figure 8 Europe: Traumatic Brain Injury Treatment Market Share, by Country, 2020
- Figure 9 Asia-Pacific: Traumatic Brain Injury Treatment Market Share, by Country, 2020
- Figure 10 Middle East & Africa: Traumatic Brain Injury Treatment Market Share, by Country, 2020
- Figure 11 Global Traumatic Brain Injury Treatment Market : Company Share Analysis, 2020 (%)
- Figure 12 Zimmer Biomet: Key Financials
- Figure 13 Zimmer Biomet: Segmental Revenue
- Figure 14 Zimmer Biomet: Geographical Revenue
- Figure 15 Neuren Pharmaceuticals Ltd: Key Financials
- Figure 16 Neuren Pharmaceuticals Ltd: Segmental Revenue
- Figure 17 Neuren Pharmaceuticals Ltd: Geographical Revenue
- Figure 20 Oxygen Biotherapeutics Inc: Key Financials
- Figure 19 Oxygen Biotherapeutics Inc: Segmental Revenue
- Figure 20 Oxygen Biotherapeutics Inc: Geographical Revenue
- Figure 21 TEVA Pharmaceutical Industries Ltd : Key Financials
- Figure 22 TEVA Pharmaceutical Industries Ltd: Segmental Revenue
- Figure 23 TEVA Pharmaceutical Industries Ltd : Geographical Revenue
- Figure 24 Ischemic: Key Financials
- Figure 25 Ischemic: Segmental Revenue
- Figure 26 Ischemic. Geographical Revenue
- Figure 27 Grace Laboratories LLC: Key Financials
- Figure 28 Grace Laboratories LLC: Segmental Revenue
- Figure 29 Grace Laboratories LLC: Geographical Revenue
- Figure 30 Cognosci: Key Financials
- Figure 31 Cognosci: Segmental Revenue
- Figure 32 Cognosci: Geographical Revenue
- Figure 33 Medicortex: Key Financials
- Figure 34 Medicortex: Segmental Revenue
- Figure 35 Medicortex: Geographical Revenue
- Figure 36 Amarantus BioScience Holdings: Key Financials
- Figure 37 Amarantus BioScience Holdings: Segmental Revenue
- Figure 38 Amarantus BioScience Holdings: Geographical Revenue
- Figure 39 Aldagen: Key Financials
- Figure 40 Aldagen: Segmental Revenue
- Figure 41 Aldagen: Geographical Revenue
- Figure 42 NeuroScience Pharmaceuticals : Key Financials
- Figure 43 NeuroScience Pharmaceuticals : Segmental Revenue
- Figure 44 NeuroScience Pharmaceuticals : Geographical Revenue
- Figure 45 Targacept: Key Financials
- Figure 46 Targacept: Segmental Revenue
- Figure 47 Targacept: Geographical Revenue
- Figure 48 BioDirection, Inc: Key Financials
- Figure 49 BioDirection, Inc: Segmental Revenue
- Figure 50 BioDirection, Inc: Geographical Revenue
- Figure 51 QuesGen Systems, Inc: Key Financials
- Figure 52 QuesGen Systems, Inc: Segmental Revenue
- Figure 53 QuesGen Systems, Inc: Geographical Revenue
- Figure 54 BrainScope Company, Inc, Inc: Key Financials
- Figure 55 BrainScope Company, Inc, Inc: Segmental Revenue
- Figure 56 BrainScope Company, Inc, Inc: Geographical Revenue
- Figure 57 Neural Analytics, Inc, Inc: Key Financials
- Figure 58 Neural Analytics, Inc, Inc: Segmental Revenue
- Figure 59 Neural Analytics, Inc, Inc: Geographical Revenue
- Figure 60 Oculogica, Inc: Key Financials
- Figure 61 Oculogica, Inc: Segmental Revenue
- Figure 62 Oculogica, Inc: Geographical Revenue
- Figure 63 BrainScope Company, Inc: Key Financials
- Figure 64 BrainScope Company, Inc: Segmental Revenue
- Figure 65 BrainScope Company, Inc: Geographical Revenue
- Figure 66 Silver Creek Pharmaceuticals Inc: Key Financials
- Figure 67 Silver Creek Pharmaceuticals Inc: Segmental Revenue
- Figure 68 Silver Creek Pharmaceuticals Inc: Geographical Revenue
- Figure 69 Stemedica Cell Technologies Inc: Key Financials
- Figure 70 Stemedica Cell Technologies Inc: Segmental Revenue
- Figure 71 Stemedica Cell Technologies Inc: Geographical Revenue
- Figure 72 Banayan Biomarkers Inc: Key Financials
- Figure 73 Banayan Biomarkers Inc: Segmental Revenue
- Figure 74 Banayan Biomarkers Inc: Geographical Revenue
- Figure 75 Vasopharm GmbH: Key Financials
- Figure 76 Vasopharm GmbH: Segmental Revenue
- Figure 77 Vasopharm GmbH: Geographical Revenue
Traumatic Brain Injuries Treatment Market Segmentation
Traumatic Brain Injuries Treatment Outlook (USD Billion, 2018-2032)
- Immediate Emergency Care
- Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
- Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
Traumatic Brain Injuries Treatment End-User Outlook (USD Billion, 2018-2032)
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Traumatic Brain Injuries Treatment Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
- North America Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- North America Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
US Outlook (USD Billion, 2018-2032)
- US Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- US Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
CANADA Outlook (USD Billion, 2018-2032)
- CANADA Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- CANADA Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
- North America Traumatic Brain Injuries Treatment by Treatment
Europe Outlook (USD Billion, 2018-2032)
- Europe Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Europe Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Germany Outlook (USD Billion, 2018-2032)
- Germany Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Germany Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
France Outlook (USD Billion, 2018-2032)
- France Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- France Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
UK Outlook (USD Billion, 2018-2032)
- UK Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- UK Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
ITALY Outlook (USD Billion, 2018-2032)
- ITALY Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- ITALY Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
SPAIN Outlook (USD Billion, 2018-2032)
- Spain Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Spain Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Rest Of Europe Outlook (USD Billion, 2018-2032)
- Rest Of Europe Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- REST OF EUROPE Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
- Europe Traumatic Brain Injuries Treatment by Treatment
Asia-Pacific Outlook (USD Billion, 2018-2032)
- Asia-Pacific Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Asia-Pacific Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
China Outlook (USD Billion, 2018-2032)
- China Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- China Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Japan Outlook (USD Billion, 2018-2032)
- Japan Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Japan Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
India Outlook (USD Billion, 2018-2032)
- India Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- India Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Australia Outlook (USD Billion, 2018-2032)
- Australia Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Australia Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
- Rest of Asia-Pacific Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Rest of Asia-Pacific Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
- Asia-Pacific Traumatic Brain Injuries Treatment by Treatment
Rest of the World Outlook (USD Billion, 2018-2032)
- Rest of the World Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Rest of the World Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Middle East Outlook (USD Billion, 2018-2032)
- Middle East Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Middle East Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Africa Outlook (USD Billion, 2018-2032)
- Africa Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Africa Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
Latin America Outlook (USD Billion, 2018-2032)
- Latin America Traumatic Brain Injuries Treatment by Treatment
- Immediate Emergency Care
Medications
- Diuretics
- Anti-Seizure Drugs
- Coma-Inducing Drugs
- Anti-Anxiety Agents
- Anti-Depressant
- Anti-Psychotics
- Analgesic
- Anti-Convulsants
- Anti-Coagulants
Surgery
- Removing Clotted Blood
- Repairing Skull Fracture
- Bleeding in the Brain
- Opening a Window in the Skull
- Rehabilitation
- Latin America Traumatic Brain Injuries Treatment by End-User
- Hospitals
- Neurologist
- Independent Pharmacies
- Rehabilitative Center Treatment
- Others
- Rest of the World Traumatic Brain Injuries Treatment by Treatment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment